By Hilary Rosselot
Healx Updates the Fragile X Community About their Fragile X Program and the IMPACT-FXS trial
Healx shares the closing of their IMPACT-FXS trial with plans to open a new study in early 2023.
Read the full letter to understand the shift in their plans and what to expect: Community statement – Update on IMPACT-FXS
Healx continues to work extensively with the NFXF’s Clinical Trials Committee within the Research Readiness Program to be sure their Fragile X program is scientifically-sound, relevant, and impactful.
Thanks, Healx, for your open and honest communication with the Fragile X community! We look forward to sharing your new study in 2023!
about
Hilary Rosselot
Hilary joined the NFXF team in 2019. Prior to joining the NFXF team, she worked at the Cincinnati Fragile X Research and Treatment Center for over five years. She has experience as a clinical research coordinator across many types of clinical trials and served as the clinical research manager for the Cincinnati program. She earned a bachelor’s degree in psychology, a master’s, and is a SOCRA certified clinical research professional (CCRP). She enjoys time with family and friends, a great book, a strong cup of coffee and, of course, a good laugh!
learn more
Rockefeller University: Potential new treatment for Fragile X targets one gene to affect many
Above: Mouse brains with Fragile X Syndrome (lower) lose the ability to regulate proteins like Brd4 (green). Photo from The Rockefeller University. A new publication in the journal Cell describes efforts by two groups at Rockefeller [...]
NFXF Survey: What Aspects Have the Greatest Impact on Lives of People with FXS?
The National Fragile X Foundation is conducting a short five-minute survey to find the aspects of Fragile X syndrome (FXS) that have the greatest impact on the lives of people with FXS and their families/caretakers. [...]